NHS Trust Opens European Site for Trial Testing Alzheimer's Drug in Asymptomatic High-Risk Adults

Unbiased summary

Surrey and Borders Partnership NHS Foundation Trust has become the first European site to open the PrevenTRON phase III clinical trial, which will test the experimental drug trontinemab on healthy adults aged 55–80 who show no memory symptoms but have elevated blood levels of p-tau217, a biomarker linked to future Alzheimer's risk. The international study aims to recruit about 1,600 participants across multiple UK and global sites. Participants will receive monthly infusions of trontinemab, a Roche-developed antibody designed to clear amyloid plaques in the brain. The trial will assess whether early intervention can prevent the onset of dementia. Previous research suggests high p-tau217 levels correlate with a significant risk of cognitive decline, and early studies of trontinemab showed rapid amyloid clearance.

Generated with deepseek-ai/deepseek-v4-flash-0731 (NIM)

Coverage by outlet

The Guardian left

Angle Emphasizes the scientific promise and shift toward prevention, framing the trial as a hopeful breakthrough in dementia research.

Bias The Guardian highlights the drug's potential and the biomarker's predictive accuracy, quoting the chief investigator on a paradigm shift. It omits the logistical complexities or potential risks of the trial, and while it notes the drug 'attacks' plaques, it frames early results as 'groundbreaking' without discussing potential side effects or limitations. The tone is optimistic and focused on the research mechanism.

Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented

The Mirror centre-left

Angle Frames the story as a 'groundbreaking' national achievement, emphasizing British leadership and the potential to help millions.

Bias The Mirror repeats the word 'breakthrough' and highlights the pride of the NHS trust, with a direct quote from the professor. It simplifies the biomarker as 'protein taul' (likely a typo for tau) and does not mention the specific p-tau217 accuracy or the previous 78% risk estimate. The coverage downplays the experimental nature of the drug and omits any mention of potential risks or the fact that it's a phase III trial. The focus is on hope and national contribution.

Alzheimer’s drug to be offered to people without symptoms to stop it developing

GB News right

Angle Presents the trial as a 'world first' and emphasises the speed and superiority of the new drug over existing treatments, with a slight nationalist tone.

Bias GB News highlights that Britain is leading Europe and calls it a 'world's first,' though the trial is international. It emphasises the 'brain shuttle' mechanism and states that the drug clears plaques faster than existing treatments, without noting that this is from early research, not conclusive. It omits the biomarker's predictive limitations and the trial's recruitment criteria (elevated p-tau217) but mentions tau protein. The tone is promotional, focusing on the drug's engineering and advancement, neglecting potential risks or the broader context of prevention trials.

Middle-aged people with NO memory problems offered Alzheimer's drug in world first